A B S T R A C T To determine the plasma epinephrine thresholds for its lipolytic effects, 60-min epinephrine infusions at nominal rates of 0.1, 0.5, 1.0, 2.5, and 5.0 jg/min were performed in each of four normal young adult men while they also received a simultaneous infusion of [1-13C] 94-101.). Increments in plasma glycerol and free fatty acids and in the inflow and outflow transport of palmitate, however, occurred at lower plasma epinephrine thresholds in the range of 75 to 125 pg/ml. Palmitate clearance was unaffected at any steady-state epinephrine level produced. These data indicate that (a) the lipolytic effects of epinephrine occur at plasma levels approximately threefold basal values and (b) lipolysis is more sensitive than glycogenolysis to increments in plasma epinephrine.
INTRODUCTION
The importance ofthe sympathetic nervous system and epinephrine in the regulation of fat metabolism has been known for more than 40 yr (1-4). Dole (5) , and Gordon and Cherkes (6) first demonstrated that epi-nephrine injection caused a prompt increase in plasma FFA levels, which Havel and Goldfein (7), using [1-14C] palmitate, showed to be the result of altered FFA transport. The rise in plasma FFA produced by catecholamine administration was subsequently confirmed in many species including man (7) (8) (9) , dog (7, (10) (11) (12) (13) , rat (14, 15) , monkey (16) , and sheep (17, 18) .
Although a pulse intravenous injection of epinephrine as small as 0.05 0gkg (7) and an infusion as little as 0. 25 ,ug/min (19) can increase plasma FFA concentrations, most investigations of catecholamine-induced lipolysis in vivo have used doses that might be expected to produce plasma catecholamine concentrations higher than those occurring under usual physiological conditions. Furthermore, since these studies were carried out before the availability of sensitive isotope derivative methods (20, 21) for measuring plasma epinephrine and norepinephrine concentrations, the plasma catecholamine levels required to produce lipolytic effects have not been well defined. In a recent study (22) , we infused adults with graded epinephrine doses to establish physiologic thresholds for this hormone's metabolic and hemodynamic actions. This study showed that plasma epinephrine thresholds for increments of plasma lactate, ,3-hydroxybutyrate, and glucose (the latter the combined result of an increased glucose production and an impaired glucose clearance) were in the range of 150 to 200 pg/ml. Plasma glycerol, however, increased with an apparent epinephrine threshold of 75-125 pg/ml suggesting that lipolysis was more sensitive to epinephrine than was glycogenolysis. In the present investigation we have pursued the above observation by directly estimating lipolysis with the nonradioactive tracer 90+2  86+4  87+3  85±1  89±2  88±2  88±4  90±4 93±4   Insulin, ,uUIml  8±1  9±2  9±2  8±2  12±1  9±1  9±1  13±3 13±3  Glucagon, pglml   110±12 111±8 105±7  112±2  108±2 103±5  98+2  105±6 95±8 * Saline control infuision.
Average of five basal values for each subject before epinephrine infusion. § Infusion values 30 min after the start of the epinephrine infusion at the indicated rate. Infusion values 60 min after the start of the epinephrine infusion at the indicated rate.
[1-13C]palmitic acid in young adults during graded epinephrine infusions. The results confirm that epinephrine will accelerate the inflow of FFA into plasma at concentrations approximately half those required to increase glucose production.
METHODS
Four normal young adult men, aged 22-26 yr, of normal weight (75.5+3 kg) and height (195±3 cm), each consented to six 120-min infusions of [1-13C] palmitic acid. During the 2nd h of each study, the subject also received a simultaneous infusion of epinephrine at one of five nominal rates (0.1, 0.5, 1.0, 2.5, and 5.0 ,ug/min) or a saline control infusion. All infusions were performed after an overnight hospitalization during which time the patient was allowed to drink water but otherwise fasted, including abstinence from alcohol, tobacco, and caffeine. Subjects were supine throughout the course of the infusion studies, which were spaced at intervals of at least 1 wk in a given subject. The epinephrine infusion sequence was varied in a fashion unknown to the individual studied.
Three intravenous catheters were placed into superficial veins in each subject 30 min before the start of the study. Two catheters for infusion of [1-_3C] palmitate and epinephrine (or saline), were placed in one arm and a sampling catheter was placed in the contralateral arm. 30 min after catheter placement, a continuous infusion of [1-_3C] palmitic acid (90 atom percent 1-13C; Merck Sharp and Dohme of Canada Limited, Quebec, Canada) complexed to essentially fatty acidfree human albumin (Sigma Chemical Co., St. Louis, Mo.) (23) was begun at the rate of0.033 umol [1-'3C]palmitate per kg * min using a calibrated syringe pump (Harvard Apparatus Co., Inc., S. Natick, Mass.). The fatty acid infusion rate was subsequently verified by measuring the palmitic acid content ofthe infused solution by gas chromatography as described below. 60 min thereafter, appropriate amounts of (-)epinephrine (adrenaline chloride, Parke, Davis & Company, Detroit, Mich.) were diluted in saline containing ascorbic acid (0.5 mg/ ml) and infused at a constant rate with a second syringe pump. Preliminary studies have shown that such infusate epinephrine concentrations are stable for 120 min at room temperature. Stability was confirmed by measuring infusate epinephrine concentrations before and after each infusion. Plasma glucose, glycerol, P-hydroxybutyrate, insulin, glucagon, and catecholamines were measured as previously described (22) . Plasma FFA were quantified by the gas chromatography method of Hagenfeldt (24) after conversion to the methyl esters with 1% sulfuric acid in methanol. Fatty acid separation was achieved using a 2-m x 2-mm column of 10% SP-2330 (Supelco Inc., Bellefonte, Pa.) held isothermal at 160°C for 2 min, then programmed to 240°C at 4°C/min. The content ofindividual FFA was determined by comparison of peak area to the area of the heptadecanoic acid internal standard. Total plasma FFA concentration was recorded as the arithmetic sum of the contents of the individual fatty acids from 12:0 to 20:4. An aliquot of the same methyl ester fraction was analyzed for plasma [1-_3C] palmitic acid enrichment by 70 eV electron impact, selected ion monitoring gas chromatography-mass spectrometry of the molecular ion region (m/z 270 and 271) of palmitate methyl ester after resolution by isothermal gas chromatography at 150°C on a 2-m x 2-mm 3% SP-2300 column. The ion monitoring was accomplished with a computer-controlled Finnigan 3300 (Finnigan Corp., Sunnyvale, Calif.) quadrupole gas chromatography-mass spectrometry system capable of measuring ion current ratios with a precision of better than ±+1% (25) , a precision in the range we attained measuring [1-_3C] palmitate enrichments using a manually controlled ion monitoring system (26) . Calibration standard solutions of known [1-_3C]-palmitic acid enrichment were run before each plasma series.
The inflow transport or rate of appearance (Ra)' of palmitate into the sampled plasma compartment and its rate of outflow transport or disappearance (Rd) were calculated by Steele's equations (27) . During the basal, preepinephrine infusion steady-state period, these equations reduce to the conventional steady-state radiotracer expression (28) R. = Rd = turnover = i/Ep 166±+12   13±3  17±6  15+3  11±2  16+4  20+2  14+4  18+7  23±9  125±+16  107±+15  103+6  113+8  103+9  101+9  104+7  97±3  91+9 where i is the infusion rate of the tracer and Ep is the tracer enrichment at plateau. For application to studies using stable isotope tracers which, in themselves, contribute slightly to the mass of the substrate pool (-0.5-2.0% in the present studies), and are labeled to an extent <100% (90% in the current instance), the above equation is modified to the form Li-
where E(t) and Q(t) are the plasma 1-13C enrichment and the palmitate pool size, respectively, at time t. The latter pool size was calculated as the product of the plasma concentration times the plasma volume taken as 5% of the body weight (30) . Because of the rapid flux of FFA, the tracer was considered to mix completely in the plasma space during the 10-min interval between samples (31). The palmitate outflow transport or disappearance rate in the nonsteady state was calculated according to Steele (27) Table I . During the saline control study, plasma glucose and hormonal levels remained unchanged from the basal, preinfusion values. As noted previously (22, 23) , epinephrine at the two highest infusion rates produced a significant (P < 0.05, paired t) rise in plasma glucose by 30 min which was accompanied by a slight, but significant (P < 0.05) increase in plasma insulin at the 2.5-,g/min infusion rate. At the 5.0-,ug/min rate, however, there was wide individual variability in insulin response. Plasma glucagon was not significantly altered at any dose of epinephrine studied, compatible with our prior results (22) . Table II shows the basal plasma fatty acid concentrations and net inflow transport rates (Ra) during the five studies in each individual. The average postabsorptive plasma palmitate and FFA concentrations were 132±7 and 549±13.9 ,uLM, respectively, values comparable to previously reported levels (32-37). Palmitate comprised an average of 24.2% of the total circulating FFA, a figure that also compares well with reported values (32, 34, 38) . The overall mean palmitate ,umol/kg per min, both values similar to those found in prior investigations (36, 37, (39) (40) (41) . As noted by others (39, (41) (42) (43) (44) , the net inflow transport of fatty acids was directly proportional to the plasma concentration (Fig. 1) . Table III Increments in plasma FFA and glycerol (Fig. 3 ) occurred at plasma epinephrine levels in the 75-125-pg/ml range, consistent with a threshold effect in that range observed for glycerol in our previous study (22) . Likewise, a similar threshold was observed for palmitate Ra and Rd (Fig. 4) . Although there was considerable I30   I  B   I3,,   10   B   I30   I,,   116+8  252+31  188+21  148±+14  388+43  270+22  117+24  396±79  304+46   498+27 1092± 119 806+77  612±34 1663± 156 1286±95  479+93 1656±327 1273±+189  46±3  85+5  64+10  61±7  126±21  84+11   50±19  125±43  72±28   69±6  118±21  153±34  100±7  258±16  378±13  101±+22   250±68  350+94 DISCUSSION In regard to substrate and hormonal alterations produced by graded epinephrine infusions, the results of the present study agree well with those of our prior report (22) . Basal and epinephrine-induced changes in glucose, insulin, lactate, glycerol, and f-hydroxybutyrate were virtually identical to those seen previously. Once again, we also saw no increase in plasma glucagon during epinephrine infusion, confirming the results of our previous study (22) but disagreeing with those of earlier investigations (45) (46) (47) . However, our failure to see a plasma glucagon decrement with the modest hyperglycemia produced by the higher epinephrine infusion rates possibly reflects epinephrine's opposing effects on stimulating pancreatic alpha cell function (45) (46) (47) (48) .
Basal, postabsorptive palmitate and total FFA content varied substantially in the same individual, a phenomenon found by others (49) . The use of the nonradioactive tracer [1-13C] palmitate, allowed us to repeatedly study basal palmitate flux, as well, in the same individual and confirmed that postabsorptive palmitate inflow transport varied between 13-28% (coefficient of variation), substantially greater than the less than 5% difference in basal glucose production found within the same individual by ourselves (22) and others (50) , but consistent with the known direct relationship between plasma FFA levels and inflow transport (7, 44, (51) (52) (53) confirmed in the present work.
The current studies also support the hypothesis inherent in our previous investigation (22) that the lipolytic actions of epinephrine are manifest at lower plasma epinephrine levels than are its hyperglycemic and ketonemic effects. As before (22) , the plasma epinephrine threshold for an increment in glycerol was in the 75-125-pg/ml range, and in the present study, a similar threshold was observed for increasing the plasma FFA level as well. This threshold contrasts with the somewhat higher plasma epinephrine values required to elevate plasma glucose, lactate, and f3-hydroxybutyrate.
The kinetic studies carried out with [1-13C] The palmitate Ra showed a virtually immediate response to an elevation in plasma epinephrine, a long-appreciated phenomenon (7) . The maximal palmitate Ra was achieved within 20-30 min and the peak palmitate concentration measured -10 min later. Thereafter, plasma palmitate inflow transport and, consequently, palmitate content declined. This decrement appears to be due, in part, to the combined effects of hyperglycemia, per se (57), a slight increase in insulin values (secondary to hyperglycemia) at the higher epinephrine infusion rates and to the rise in lactate seen at higher p[E],,, since lactate is known to inhibit fat mobilization (54) .
It is noteworthy that the increase in palmitate Ra occurs at plasma epinephrine values barely threefold the average basal value of 34+18 pg/ml of 60 normal subjects studied in our laboratory (58) . This magnitude of epinephrine rise is only slightly greater than that achieved during quiet standing (59) and in the range found in subjects smoking cigarettes (60) . Furthermore, the epinephrine threshold for its lipolytic effects is far below plasma epinephrine values encountered during exercise (61), myocardial infarction (62), diabetic ketoacidosis (63) , and surgical procedures (22) . Clearly, then, circulating epinephrine levels are more than sufficient to account for the lipolysis seen in these circumstances and long attributed to catecholamines. The effect of the circulating norepinephrine threshold on lipolysis was not addressed in the present study. Norepinephrine infusion rates of [4] [5] ,ug/min in man (64) and 0.05 ,ug/kg per min in the dog (65) can elevate plasma FFA levels. We have shown (66) that these rates (the latter approximately equal to the former for a 70-kg subject) produce circulating norepinephrine levels in the range of 1,400-2,100 pg/ml, at which level we also saw an increase in plasma glycerol. Although this norepinephrine range is reached during exercise (61) , and with illnesses such as ketoacidosis (63) and myocardial infarction (67) , it is rarely approached under ordinary physiological circumstances. Thus, under usual conditions, it appears that the lipolytic actions of norepinephrine may be limited to its long recognized local effector role as sympathetic neurotransmitter at nerve endings in adipose tissue.
We conclude that (a) small increments in plasma epinephrine can induce lipolysis, (b) lipid mobilization is more sensitive than glucose production to increases in plasma epinephrine, and (c) circulating epinephrine is -15-20-fold more potent than norepinephrine in promoting liposlysis.
